Blepharitis

Latest News

Image Credit: © ohishift - stock.adobe.com
Safety, efficacy of lotilaner ophthalmic solution for Demodex blepharitis treatment

March 31st 2023

Though there is no current FDA-approved treatment, lotilaner ophthalmic solution, 0.25%, is the first drug designed to treat and target the underlying cause of Demodex blepharitis.

SECO 2023: Drugs of the future
SECO 2023: Drugs of the future

March 2nd 2023

Eye care therapies on the move: What’s in the pipeline
Eye care therapies on the move: What’s in the pipeline

September 16th 2022

Effective treatments for presbyopia, myopia, demodex
Effective treatments for presbyopia, myopia, demodex

March 12th 2022

Protect patients’ eyes by encouraging a three-step ocular wellness regimen
Protect patients’ eyes by encouraging a three-step ocular wellness regimen

October 9th 2020

Video Series
Video Interviews
Latest CME Events & Activities

Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data

View More

Practical Approaches to Modern Dry Eye Treatment and Management

June 25, 2025

Register Now!

Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy

View More

Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)

View More

Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)

View More

Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)

View More

Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)

View More

Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (CME Credit)

View More

Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (COPE Credit)

View More

Retina Specialists: Join us in Long Beach

July 31, 2025 - August 2, 2025

Register Now!

SimulatED™: Pioneering Treat-and-Extend Therapy—The Impact of Early Application

View More

3rd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between

September 6, 2025

Register Now!

Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C/D

View More

EyeCon 2025

September 26-27, 2025

Register Now!

Optometrists: Earn COPE CE Credits in Portland or Virtually

October 16-17, 2025

Register Now!

Join us at The Ophthalmology Meeting in Orlando this October

October 18, 2025

Register Now!

Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (Cope Credit)

View More

Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

Expert Perspectives on Technological Advances in Cataract Surgery

View More

Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy

View More

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

View More

(CME Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

View More

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

View More

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

View More

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

View More

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

View More

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

View More

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

View More

More News

© 2025 MJH Life Sciences

All rights reserved.